

25 November 2022 ASX Code: MXC

Results of the 2022 Annual General Meeting

LSE Code: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to announce the results of voting on resolutions put to the Company's shareholders at its 2022 Annual General Meeting, held on 24 November 2022. This information is provided in accordance with Section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

The Company advises that all resolutions put the meeting were decided on a poll, with the results of voting detailed in the accompanying table.

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.eu

UK Financial and Corporate Advisor

Hannam & Partners

Rupert Fane / Nilesh Patel +44 7810 056 104 rf@hannam.partners / nilesh@hannam.partners

UK PR Advisors

Tavistock

Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk

MGC Pharmaceuticals Ltd

David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.eu

UK Broker Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels









MGC Pharmaceuticals Ltd ANNUAL GENERAL MEETING Thursday, 24 November 2022 **Results of Meeting**

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll			Resolut
Resolution	Resolution Type	For	(as at pro	Proxy's Discretion	Abstain	For	where applicable Against	Abstain*	Resu Carried Not Car
1. Adoption of Remuneration Report	Ordinary	304,942,266 94.52%	9,827,660 3.05%	7,845,668 2.43%	136,249,209	320,451,602 96.95%	9,827,660 3.05%	136,249,209	Carr
2. Re-election of director - Stephen Parker	Ordinary	449,523,692 97.16%	5,316,595 1.15%	7,818,978 1.69%	2,000,539	464,979,648 98.85%	5,316,595 1.15%	2,000,539	Carr
3. Re-election of director - Brett Mitchell	Ordinary	448,957,163 97.04%	5,883,124 1.27%	7,818,978 1.69%	2,000,539	464,413,119 98.73%	5,883,124 1.27%	2,000,539	Carr
4. Approval of 7.1A Mandate	Special	444,413,201 96.29%	8,396,251 1.82%	8,739,162 1.89%	3,111,190	461,709,525 98.18%	8,396,251 1.82%	3,111,190	Carri
5. Ratify Convertible Notes	Ordinary	360,644,894 94.01%	15,176,188 3.96%	7,818,978 2.03%	81,019,744	376,100,850 96.04%	15,176,188 3.96%	81,019,744	Carri
6. Ratify Issue of Shares	Ordinary	350,967,499 93.21%	17,689,740 4.70%	7,878,978 2.09%	88,123,587	366,543,455 95.30%	17,689,740 4.70%	88,123,587	Carri
7. Employee Securities Plan	Ordinary	291,948,020 92.47%	15,947,534 5.05%	7,818,978 2.48%	148,945,272	307,403,976 94.95%	15,947,534 5.05%	148,945,272	Carri
^k Votes cast by a person who abstains on ar	n item are not counte	ed in calculating the re	quired majority on a	poll.					